Visual Hallucinations in Progressive Supranuclear Palsy

Spiridon Papapetropoulos Deborah C. Mash

Department of Neurology, University of Miami, Miller School of Medicine, Miami, Fla., USA

Dear Sir,

Progressive supranuclear palsy (PSP) is the most common and best recognized atypical parkinsonian syndrome. The clinical characteristics of PSP as described by Steele, Richardson and Olszewsky [1] in 1964 include parkinsonian features, postural instability, vertical supranuclear gaze palsy, pseudobulbar symptoms and cognitive decline. However, it has been widely recognized that PSP is characterized by an ever-expanding and ‘diverse’ clinical phenotype [2] that among others includes a florid neuropsychiatric symptomatology [3]. This report focuses on the description of hallucinations in a small cohort of clinically and pathologically diagnosed PSP patients.

Our study population consisted of 22 consecutive PSP patients. All subjects consented during life to donate their brains to the University of Miami Brain Endowment Bank™. Brain donors were recruited and registered with the Brain Bank through a campaign performed throughout the United States over the last decade. All brains were formalin-fixed and sectioned according to standard protocols [6]. Neuropathologic diagnosis of PSP was based on well-accepted criteria, using conventional staining techniques [7]. The study was approved by the local institutional review board.

Among 22 patients [15 (68.2%) men and 7 (37.8%) women] with PSP [mean age at onset 67.0 years (SD 9.5), at death 72.9 years (SD 8.4) and disease duration from symptom onset to death 5.5 years (SD 2.5)], 2 (9.1%) experienced visual hallucinations during the course of their disease. One of the two patients also complained of auditory hallucinations. Two factors of potential importance should be considered about our cohort: 11 (50%) had a disease duration of more than 4 years and 16 (72.7%) were on L-dopa for more than 5 years.

The neuropathological findings in both cases with hallucinations were typical of PSP: case 1 had no significant neocortical nigral gliosis and neuronal loss, with substantial white matter lesions. Case 2 demonstrated enough pathologic features to satisfy the CERAD diagnostic criteria for probable Alzheimer’s disease [6]. Both cases demonstrated extensive substantia nigral gliosis and neuronal loss, with extraneuronal neuromelanin and neurofibrillary...
tangles (NFTs). NFTs were also seen in thalamus and other basoganglionic structures in both cases. A detailed description of the characteristics of our PSP cohort is provided elsewhere [2].

Case 1: A right-handed, Caucasian female was diagnosed with parkinsonism at the age of 69 when she noted a progressive lack of coordination of her left upper limb followed (a few months later) by postural instability and falls. The patient was subsequently started on L-dopa with moderate response. She eventually (over a period of 2 years) developed all of the characteristic features of PSP including vertical gaze palsy, marked axial rigidity, bradykinesia, and pseudobulbar symptomatology with swallowing difficulties. About 5 years into her disease and while on low doses of L-dopa (300 mg/day) and selegiline (10 mg/day) she started having vivid nightmares which she had difficulty discerning from reality. About 1 year later and while her cognitive function was moderately affected, she started experiencing visual hallucinations. For a period of about 1 year they remained benign. She would constantly see the same image of her son’s dog. The image was present for a few seconds and then would suddenly vanish. Subsequently, her hallucinations became more frequent, prolonged, complex and frightening and she also started experiencing auditory hallucinations (threatening voices). She was placed on risperidone (0.5 mg/day) with moderate improvement in her symptoms. However, after an exacerbation of her parkinsonian symptoms (mainly rigidity) this was gradually replaced by clozapine (up to 50 mg/day), which failed to produce the same effect. About 7 years into her disease L-dopa was discontinued because of loss of function. However, neither the intensity nor the characteristics of the hallucinations were affected by the discontinuation of L-dopa. The patient’s psychotic symptomatology responded mildly to a combination of clozapine and bupropion hydrochloride. She died due to complications of PSP 1 year later.

Case 2: A right-handed, Caucasian male was diagnosed with parkinsonism at the age of 59 after he developed an atypical (6- to 8-Hz) resting tremor of his right hand. He was gradually started on L-dopa (400 mg/day), with mild (about 40%) improvement. His condition deteriorated over the next few years with marked axial rigidity and bradykinesia. About 5 years into his disease the patient was diagnosed with PSP after developing a rather typical symptomatology, including a disturbance of vertical gaze, an increasing disturbance in balance, swallowing difficulties and moderate cognitive impairment. A trial of amantadine and an increase in the L-dopa dose (up to 800 mg/day) failed to provide further symptomatic relief. There was considerable sleep disturbance with fragmentation and daytime sleepiness, partly treated with zolpidem tartrate. At the same time, while under L-dopa (400 mg/day) and about 5.5 years into his disease the patient started experiencing benign visual hallucinations. They consisted of ‘friendly’ fragmented faces that appeared in dim surroundings. They lasted for a few minutes and then disappeared. His medical history, review of systems and neuroimaging at the time did not indicate any triggering factors. There was no therapeutic intervention for the hallucinatory symptoms since they remained benign and spontaneously remitted about 1 year later, never to reappear. The patient died a few years later of aspiration pneumonia.

We report here our findings on the characteristics of hallucinations from a small cohort of PSP patients. Only 2 out of 22 PSP patients (9.1%) reported visual hallucinations. Case 1 had auditory in addition to visual hallucinations. The hallucinatory experience was somewhat similar to that described by Parkinson’s disease (PD) patients (for review see [8]). Symptoms were a late complication of the disease, developing several years after onset. Both patients were on long-term dopaminergic replacement therapy although there was no clear relation between symptom development and treatment parameters. Sleep abnormalities (vivid dreaming and fragmentation, respectively) preceded and significant cognitive impairment accompanied the development of the hallucinations, in accordance with the continuum theory [9]. The symptoms improved with antipsychotic therapy in one patient that tried it. However, both cases presented here had additional atypical features: in case 1 the hallucinations did not subside after the discontinuation of L-dopa and in case 2 the symptoms remitted spontaneously, without discontinuation of therapy.

Hallucinations (mainly visual) are particularly common in PD and are present in about 20–40% of patients [10]. They are usually drug-related, although other factors may be important (i.e. cognitive impairment, disease severity and duration) [10, 11]. They have a major impact on the natural history of PD and have been identified as one of the cardinal risk factors for nursing home placement [12]. Hallucinations have been less frequently reported in PSP. A study comparing neuropsychiatric features of PD versus PSP patients found that hallucinations were reported in only 1 of the 27 PSP patients who were treated with dopaminergic agents, and concluded that regional neurochemical differences in cholinergic and monoaminergic degeneration may provide possible explanations for the finding of more frequent hallucinations in PD than in PSP patients [3]. In our cohort 2 out of 11 patients (18.2%) that received chronic treatment with dopaminergic agents developed hallucinations.

Similarities in the characteristics of hallucinations described in PD and PSP suggest the involvement of similar mechanisms (dernervation supersensitivity of mesocortical and mesolimbic dopaminergic receptors and other neurotransmitter imbalances [8]) in their development. Factors that may account for the differences in the frequency of visual hallucinations between PSP and PD patients (our previously reported frequency of hallucinations in PD patients of our Brain Bank cohort is 52.2% [13]) are: (a) regional neurochemical differences in cholinergic and monoaminergic degeneration; (b) the decreased survival of PSP versus PD patients and (c) the early discontinuation of dopaminergic treatment due to loss of efficacy. Our report has certain limitations commonly seen in retrospective studies. The possibility of incomplete symptom recording as well as ascertainment and small sample bias should be considered. Larger prospective studies on the characteristics and prevalence of hallucinations in PSP are warranted.

Acknowledgments

The Brain Endowment Bank™ is funded in part by the National Parkinson Foundation (NPF). This work was supported in part by a grant from the National Parkinson Foundation (NPF 662891).

References
